Is aplastic osteodystrophy a disease of malnutrition?

Current Opinion in Nephrology and Hypertension

Volumn 9, Issue 4, 2000, Pages 363-367

  Fukagawa, Masafumi ^a   Akizawa, Tadao ^b   Kurokawa, Kiyoshi ^c  

^a KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^c TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

22 OXACALCITRIOL; PARATHYROID HORMONE;

AGING; DIABETES MELLITUS; DIALYSIS; FRACTURE; HUMAN; HYPERMAGNESEMIA; HYPOPARATHYROIDISM; MALNUTRITION; OSTEODYSTROPHY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; VITAMIN INTAKE;

HUMANS; HYPOPARATHYROIDISM; KIDNEY FAILURE, CHRONIC; NUTRITION DISORDERS; PARATHYROID HORMONE; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; RENAL DIALYSIS; RENAL OSTEODYSTROPHY; UREMIA;

EID: 0033946103     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-200007000-00007     Document Type: Review

References (65)

1. 1 Ott SM, Maloney NA, Coburn JW, et al. The prevalence of bone aluminum deposition in renal osteodystrophy and its relation to the response to calcitriol therapy. N Engl J Med 1982; 307:709-713.
2. 2 Malluche HH, Monier Faugere MC. Risk of adynamic bone disease in dialyzed patients. Kidney Int Suppl 1992; 38:S62-S67.
3. 3 Sherrard DJ, Hercz G, Pei Y, et al. The spectrum of bone disease in endstage renal failure-an evolving disorder. Kidney Int 1993; 43:436-442.
4. 4 Torres A, Lorenzo V, Hernandez D, et al. Bone disease in predialysis, hemodialysis and CAPD patients: evidence for a better response to PTH. Kidney Int 1995; 47:1434-1442.
5. 5 Ballanti P, Wedard BM, Bonucci E. Frequency of adynamic bone disease and aluminum storage in Italian uraemic patients: retrospective analysis of 1429 iliac crest biopsies. Nephrol Dial Transplant 1996; 11:663-667.
6. 6 Weinreich T. Prevention of renal osteodystrophy in peritoneal dialysis. Kidney Int 1998; 54:2226-2233.
7. 7 Sherrard DJ, Ott S, Malony N. Renal osteodystrophy: classification, cause and treatment. In: Frame B, Potts Jr JT (editors) Clinical disorders of bone and mineral metabolism. Amsterdam: Excerpta Medica; 1983. pp. 254-259.
8. 8 Quarles LD, Lobaugh B, Murphy G. Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab 1992; 75:145-150.
9. 9 Hercz G, Pei Y, Manuel A, et al. Aplastic osteodystrophy without aluminum: the role of 'suppressed' parathyroid function. Kidney Int 1993; 860-866.
10. 10 Akizawa T, Kinugasa E, Akiba T, et al. Incidence and clinical characteristics of hypoparathyroidism in dialysis patients. Kidney Int Suppl 1997; 62:S72-S74.
11. 11 Smans KA, Van Landeghem FG, DHaese PC, et al. Is there a link between erythropoietin therapy and adynamic bone disease? Nephrol Dial Transplant 1996; 11:1248-1249.
12. 12 Pei Y, Hercz G, Greenwood C, et al. Risk factors for renal osteodystrophy: a multivariant analysis. J Bone Miner Res 1995; 10:149-156.
13. 13 Couttenye MM, D'Haese PC, Deng JT, et al. High prevalence of adynamic bone disease diagnosed by biochemical markers in a wide sample of the European CAPD population. Nephrol Dial Transplant 1997; 12:2144-2150.
14. 14 Navarro JF, Mora C, Jimenez A, et al. Relationship between serum magnesium and parathyroid hormone levels in hemodialysis patients. Am J Kidney Dis 1999; 34:43-48.
15. 15 Jara A, Bover J, Felsenfeld AJ. Development of secondary hyperparathyroidism and bone disease in diabetic rats with renal failure. Kidney Int 1995; 47:1746-1751.
16. 16 Sugimoto T, Ritter C, Morrissey J, et al. Effects of high concentration of glucose on PTH secretion in parathyroid cells. Kidney Int 1990; 37:1522-1527.
17. 17 Sanchez CP, Salusky IB, Kuizon BD, et al. Growth of long bones in renal failure: roles of hyperparathyroidism, growth hormone and calcitriol. Kidney Int 1998; 54:1879-1887.
18. 18 Goodman WG, Ramirez JA, Belin TR, et al. Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 1994; 46:1160-1166.
19. 19 Ikeda K, Ogata E. The effect of vitamin D on osteoblasts and osteoclasts. Curr Opin Orthop 1999; 10:339-343.
20. 20 Akizawa T, Kinugasa E, Kurihara R, et al. Risk factors for the development of parathyroid hormone deficiency in dialysis patients. J Am Soc Nephrol 1998; 9:561A.
21. 21 Avram MM, Sreedhara R, Oo KK, et al. Prognostic value of enrollment nutritional markers including novel predictors PTH and prealbumin in hemodialysis patients: 12 years of follow-up. J Am Soc Nephrol 1999; 10:272A.
22. 22 Avram MM, Sreedhara R, Henry A, et al. Correlates of survival in peritoneal dialysis: 15 years of follow-up. J Am Soc Nephrol 1999; 10:311A.
23. 23 Usami T, Mizuno T, Ushiyama T, et al. High incidence of hypoparathyroidism in inpatients on chronic hemodialysis. J Jpn Soc Dial Ther 1998; 31:131-137.
24. 24 Kurz P, Monier Faugere MC, Bognar B, et al. Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int 1994; 46:855-861.
25. 25 Hercz G, Sherrad DJ, Chan W, et al. Aplastic osteodystrophy: follow up after 5 years. J Am Soc Nephrol 1994; 5:851A.
26. 26 Akizawa T, Kinugasa E, Kurihara S, et al. Parathyroid hormone deficiency is an indicator of poor nutritional state and prognosis in dialysis patients. J Am Soc Nephrol 1999; 10:616A.
27. 27 Avram MM, Sreedhara R, Avram DV, et al. Enrollment parathyroid hormone level is a new marker of survival in hemodialysis and peritoneal dialysis therapy for uremia. Am J Kidney Dis 1996; 28:924-930.
28. 28 Atsumi K, Kushida K, Yamazaki K, et al. Risk factors for vertebral fractures in renal osteodystrophy. Am J Kidney Dis 1999; 33:287-293. The relationship between pathological fracture, bone mineral density (BMD), and bone metabolic markers was examined in 187 regular hemodialysis patients. Greater risk of vertebral fracture in patients with lower intact PTH and BMD levels was clearly demonstrated.
29. 29 Kurihara S, Akiba T, Koiwa M, et al. Clinicopathological studies of nontraumatic fractures in hemodialysis patients. Blood Purif 1999; 17:223.
30. 30 Suda T, Takahashi N, Udagawa N, et al. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999; 20:345-357.
31. 31 Komori T, Kishimoto T. Cfba1 in bone development. Curr Opin Genet Dev 1998; 8:494-499.
32. 32 Massry SG, Coburn JW, Lee DB, et al. Skeletal resistance to parathyroid hormone in renal failure. Studies in 105 human subjects. Ann Intern Med 1973; 78:357-364.
33. 33 Hutchinson AJ, Whitehouse RW, Boulton HF, et al. Correlation of bone histology with parathyroid hormone, vitamin D and radiology in end-stage renal disease. Kidney Int 1993; 44:1071-1077.
34. 34 Salusky IB, Ramirez JA, Oppenheim W, Gales B, Segre GV, Goodman WG. Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD. Kidney Int 1994; 45:253-258.
35. 35 Qi Q, Monier-Faugere MC, Geng Z, et al. Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Am J Kidney Dis 1995; 26:622-631.
36. 36 Llach F, Massry SG, Singer FR, et al. Skeletal resistance to endogenous parathyroid hormone in pateints with early renal failure. A possible cause for secondary hyperparathyroidism. J Clin Endocrinol Metab 1975; 41:339-345.
37. 37 Bover J, Jara A, Trinidad P, et al. Dynamics of skeletal resistance to parathyroid hormone in the rat: effect of renal failure and dietary phosphorus. Bone 1999; 25:279-285.
38. 38 Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998; 95:3597-3602.
39. 39 Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93:165-176.
40. 40 Anderson MA, Maraskovsky E, Billingsley WL, et al. A homologue of TNF receptor and its ligand enhance T-cell growth and dendric-cell function. Nature 1997; 390:175-179.
41. 41 Urena P, Ferreria A, Morieux C, et al. PTH/PTHrP receptor mRNA is down-regulated in epiphysial cartilage growth plate in uremic rats. Nephrol Dial Transplant 1996; 11:2008-2016.
42. 42 Urena P, Kubrusly M, Mannstadt M, et al. The renal PTH/PTHrP receptor is down-regulated in rats with chronic renal failure. Kidney Int 1994; 45:605-611.
43. 43 John MR, Goodman WG, Gao P, et al. A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: Implications for PTH measurement in renal failure. J Clin Endocrinol Metab 1999; 84:4287-4290. By 'whole PTH assay', possible overestimation of biologically active PTH by conventional intact PTH assay was suggested. This assay may be useful for the evaluation of renal osteodystrophy, especially for adynamic bone disease.
44. 44 Lepage R, Roy L, Brossard JH, et al. A non-(1-84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples. Clin Chem 1998; 44:805-809.
45. 45 Slatopolsky E, Finch JL, Clay P, et al. A novel mechansiam for skeletal resistance in uremia (abstract). J Am Soc Nephrol 1999; 10:625A.
46. 46 Yasuda H, Shima N, Nakagawa N, et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998; 139:1329-1337.
47. 47 Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89:309-319.
48. 48 Hofbauer LC, Khosla S, Dunstan CR, et al. The role of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000; 15:2-12. This is a concise review on osteoprotegerin and its ligand. Very helpful to understand different names for a single molecule.
49. 49 Yamamoto M, Murakami T, Nishikawa M, et al. Hypocalcemic effect of osteoclastogenesis inhibitory factor/osteoprotegerin in the thyroparathyroidectomized rat. Endocrinology 1998; 139:4012-4015.
50. 50 Kazama JJ, Shigematsu T, Tsuda E, et al. Increased circulating osteoprotegerin/osteoclastogenesis inhibitory factor (OPG/OCIF) in patients with chronic renal failure. J Am Soc Nephrol 1999; 10:599A.
51. 51 Indridason OS, Quarles D. Comparison of treatment for mild secondary hyperparathyroidism in hemodialysis patients. Kidney Int 2000; 57:282-292.
52. 52 Hruska K. New concepts in renal osteodystrophy. Nephrol Dial Transplant 1998; 13:2755-2760.
53. 53 Andress DL, Howard GA, Birnbaum RS. Identification of a low molecular weight inhibitor of osteoblast mitogenesis in uremic plasma. Kidney Int 1991; 39:942-945.
54. 54 Jehle PM, Jehle DR, Mohan S, et al. Renal osteodystrophy: new insights in pathophysiology and treatment modalities with special emphasis on the insulin-like growth factor system. Nephron 1998; 79:249-264.
55. 55 Weinreich T, Zapf J, Schmidt Gayk H, et al. Insulin-like growth factor 1 and 2 serum concentrations in dialysis patients with secondary hyperparathyroidism and adynamic bone disease. Clin Nephrol 1999; 51:27-33.
56. 56 Jehle PM, Ostertag A, Schulten K, et al. Insulin-like growth factor system components in hyperparathyroidism and renal osteodystrophy. Kidney Int 2000; 57:423-436. Serum concentrations of IGF-I, IGF-II, IGFBP 1-6 and biochemical bone markers were examined in this study. The authors suggest that marked elevated IGFBP-4 levels and lower IFGBP-5 levels may contribute to diminished bone formation in uremia.
57. 57 McIntyre CW, Schroeder NJ, Burrin JM, et al. Effects of new analogues of vitamin D on bone cells: Implications for treatment of uremic bone disease. Kidney Int 1999; 55:500-511. The authors demonstrated that new vitamin D analogs induced interleukin-6 release from osteoblastic cells at much lower concentration than that of calcitriol. These data suggest that such new vitamin D analogs may have more preferable effects on bone turnover with less suppression of PTH.
58. 58 Monier-Faugere M-C, Geng Z, Friedler RM, et al. 22-Oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure. Kidney Int 1999; 55:821-832.
59. 59 Hirata M, Katsumata K, Masaki T, et al. 22-Oxacalcitriol (OCT) amelioates high turnover bone and marked osteitis fibrosa in rats with slowly progressive nephritis. Kidney Int 1999; 56:2040-2047. In these two papers, effects of 22-oxacalcitriol in parathyroid function and bone turnover were extensively examined in animal models of uremia.
60. 60 Takeyama K, Matsushiro Y, Fuse H, et al. Selective interaction of vitamin D receptor with transcriptional coactivators by a vitamin D analog. Mol Cell Biol 1999; 19:1049-1055. The authors clearly demonstrated that different sets of transcriptional coactivators are selectively utilized by an individual vitamin D analog. These data may explain different modes of action depending upon vitamin D analogs.
61. 61 Montenego J, Saracho R, Gonzalez O, et al. Reversibility of parathyroid gland suppression in CAPD patients with low I-PTH levels. Clin Nephrol 1997; 48:359-363.
62. 62 Kondo M, Hyodo T, Sakai T. Vitamin D3 withdrawal in hemodialysis patients with adynamic bone disease (letter). Nephron 1998; 80:89.
63. 63 Nemeth EF, Fox J, Delmar EG, et al. Stimulation of parathyroid hormone secretion by a small molecule antagonist of the calcium receptor. Bone 1998; 23:S156.
64. 2+ receptor stimulates PTH secretion and bone turnover in osteopenic ovariectomized rats. Bone 1998; 23:S163.
65. 65 Fukagawa M. Cell biology of parathyroid hyperplasia in uremia. Am J Med Sci 1999; 317:377-382.